The presence of emphysema does not affect the systemic bioactivity of inhaled fluticasone in severe chronic obstructive pulmonary disease

British Journal of Clinical Pharmacology

Volumn 57, Issue 4, 2004, Pages 388-392

  Lee, Daniel K C ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Alveolar absorption; Chronic obstructive pulmonary disease; Fluticasone propionate; Inhaled corticosteroids; Systemic bioactivity

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE; FORMOTEROL; HYDROCORTISONE; IPRATROPIUM BROMIDE; OSTEOCALCIN; OXITROPIUM BROMIDE; SALMETEROL; SALMETEROL XINAFOATE; THEOPHYLLINE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG ABSORPTION; DRUG ACTIVITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYDROCORTISONE URINE LEVEL; LUNG ALVEOLUS; MALE; METERED DOSE INHALER; OPEN STUDY; PRIORITY JOURNAL; SIDE EFFECT;

ADMINISTRATION, INHALATION; ANDROSTADIENES; BRONCHODILATOR AGENTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; OSTEOCALCIN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA;

EID: 1942455408     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.02026.x     Document Type: Article

References (17)

1. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000; 320: 1297-303.
2. Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003; 21: 68-73.
3. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166: 1358-63.
4. Lipworth BJ. The ISOLDE trial. Side effects with inhaled steroids should not be forgotten. Br Med J 2000; 321: 1349.
5. Singh SD, Whale C, Houghton N, Daley-Yates P, Kirby SM, Woodcock AA. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. Br J Clin Pharmacol 2003; 55: 375-81.
6. Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356: 556-61.
7. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 2001; 46: 798-825.
8. American Thoracic Society. Standardization of Spirometry. 1994 Update. Am J Respir Crit Care Med 1995; 152: 1107-36.
9. Wilson AM, McFarlane LC, Lipworth BJ. Effects of low and high doses of inhaled flunisolide and triamcinolone acetonide on basal and dynamic measures of adrenocortical activity in healthy volunteers. J Clin Endocrinol Metab 1998; 83: 922-5.
10. Weiner P, Berar-Yanay N, Davidovich A, Magadle R. Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest 1999; 116: 931-4.
11. Harrison TW, Tattersfield AE. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 2003; 58: 258-60.
12. Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000; 94(Suppl B): S3-S9.
13. Wilson AM, Lipworth BJ. 24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax 1999; 54: 20-6.
14. Mcintyre HD, Mitchell CA, Bowler SD, Armstrong JG, Wooler JA, Cowley DM. Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens. Thorax 1995; 50: 1280-4.
15. Clark DJ, Lipworth BJ. Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. Thorax 1996; 51: 981-4.
16. Dempsey OJ, Wilson AM, Coutie WJ, Lipworth BJ. Evaluation of the effect of a large Volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler. Chest 1999; 116: 935-40.
17. Wilson AM, Sims EJ, Lipworth BJ. Dose-response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. Clin Endocrinol (Oxf) 1999; 50: 329-35.